The Significance of Duration of Chemotherapy Interruptions Due to Interval Surgery in Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy |
| |
| Affiliation: | 1. Section of General Internal Medicine, Boston University School of Medicine, Boston, MA; Boston Medical Center, Boston, MA, USA;2. Data Coordinating Center, Boston University School of Public Health, Boston, MA, USA;3. Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA;4. Center for Health Care Studies, Institute for Public Health and Medicine, Northwestern University, Chicago, IL, USA;5. College of Computer and Information Science, Northeastern University, Boston, MA, USA;1. School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC, Canada V6T 1Z3;2. Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Research Institute, 7th Floor, 828 West 10th Avenue, Research Pavilion, Vancouver, BC, Canada V5Z 1M9;3. Centre for Health Evaluation and Outcome Sciences, St. Paul׳s Hospital, 588-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6;1. Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania;2. Department of Radiology, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania;3. Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania;4. Department of Otolaryngology, Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania;1. NIVEL, Netherlands Institute for Health Services Research, Utrecht, The Netherlands;2. Department of Medical Psychology, Academic Medical Center, University of Amsterdam, The Netherlands;3. Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands;4. Faculty of Health Sciences, University College of Southeast Norway, Drammen, Norway;1. Division of Hematology-Oncology, Division of Internal Medicine and the Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA;2. Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA;1. Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA;2. Faculty of Medicine, American University of Beirut, Beirut, Lebanon;3. Department of Oncologic Sciences, University of South Florida College of Medicine, Tampa, FL, USA;4. Division of Hematopathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA |
| |
| Abstract: | ObjectiveTo examine the prognostic significance of interruptions to chemotherapy arising from delayed primary surgical debulking following neoadjuvant chemotherapy in women undergoing treatment for ovarian cancer.MethodsWe carried out a retrospective chart review to identify women with ovarian cancer who were treated with neoadjuvant chemotherapy and planned delayed primary surgical debulking. Cox regression modelling was used to identify significant predictors of progression-free and overall survival, using well-established prognostic variables and time delays between courses of chemotherapy perioperatively, stratified by residual disease status.ResultsNinety-seven patients with complete data were identified. Their median age was 65.4 years. Fifty-four patients (56%) were left with optimal residual disease (< 1 cm), and 43 patients had suboptimal residual disease. The median delay from the last cycle of chemotherapy to the time of surgery was 29 days (range 20–72). The median delay from surgery to resumption of cytotoxic therapy was 23 days (range 8–65). Chemotherapy courses were interrupted for a median of 50 days (range 36–119) around the time of surgery. No effect was observed on progression-free interval by interruptions to chemotherapy, regardless of residual disease status. With respect to overall survival, the time to resumption of chemotherapy in days and the time delay in days between the two chemotherapy cycles peri-operatively were identified as statistically significant predictors only in patients with suboptimal residual disease. In patients with optimal residual disease status, neither the time of interruption between the two chemotherapy cycles peri-operatively nor the time to resumption of chemotherapy after surgical debulking was significantly predictive of overall survival.ConclusionIn women undergoing treatment for ovarian cancer, the interval between surgery and the resumption of chemotherapy in patients with suboptimal residual disease should be kept as short as possible. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
